Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S FDA has granted the company Fast Track designation for irinotecan liposome injection (Onivyde) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need.
Product Name : Onivyde
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2020
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
